Search clinical trials for: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

Total 108 results

Sanofi
Regeneron Pharmaceuticals

Completed

Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer

Neoplasms | Cancer of the Ovary

United States, France, Canada, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland
Sanofi
Regeneron Pharmaceuticals

Completed

AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

Ovarian Neoplasms

United States, Italy, Sweden
Sanofi
Regeneron Pharmaceuticals

Completed

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

Neoplasms, Lung | Pulmonary Diseases

United States, France, Canada
Sanofi
Regeneron Pharmaceuticals

Completed

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Ovarian Neoplasms | Ascites

United States, Canada, Spain, India, Belgium, Austria, Hungary, Israel, United Kingdom
National Cancer Institute (NCI)

Completed

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

Pancreatic Neuroendocrine Carcinoma | Multiple Endocrine Neoplasia Type 1

United States
National Cancer Institute (NCI)

Completed

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Ovarian Carcinoma | Pancreatic Neuroendocrine Tumor | Unresectable Solid Neoplasm | Fibrolamellar Carcinoma

United States
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer

Canada
National Cancer Institute (NCI)

Completed

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

Fallopian Tube Cancer | Uterine Carcinosarcoma | Stage IV Ovarian Epithelial Cancer | Ovarian Sarcoma | Recurrent Uterine Sarcoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Carcinosarcoma | Female Reproductive... and other conditions

United States, Canada
National Cancer Institute (NCI)

Completed

Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Metastatic Breast Cancer

Metastatic Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Endometrial Carcinoma

United States
Sanofi
Regeneron Pharmaceuticals

Terminated

Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer (VANILLA)

Pancreatic Neoplasm

United States, France, Canada, Poland, Romania, Russian Federation, Germany, Italy, Spain, Switzerland, Bulgaria, India, Belgium, Czech Republic, Mexico, Argentina, Hungary, Colombia, Slovakia, Chile, Austria, Greece, Puerto Rico, Cyprus
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage III Melanoma | Extraocular Extension Melanoma

United States
National Cancer Institute (NCI)

Terminated

Aflibercept in Treating Patients With Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | de Novo Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Completed

Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer

Metastatic Renal Cell Carcinoma

United States, Peru
National Cancer Institute (NCI)

Terminated

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

Neoplasms

United States
National Cancer Institute (NCI)

Completed

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
National Cancer Institute (NCI)

Terminated

Aflibercept for Relapsed Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
Sanofi
Regeneron Pharmaceuticals; NSABP Foundation Inc

Completed

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen (VELOUR)

Neoplasm Metastasis | Colorectal Neoplasms

Italy, Austria, Estonia, Spain, South Africa, Belgium, Puerto Rico, United Kingdom, Sweden, United States, Argentina, Australia, Brazil, Chile, Czech Republic, Denmark, France, Germany, Greece, Korea, Republic of, Netherlands, New... and more
Sanofi
Regeneron Pharmaceuticals

Completed

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (VITAL)

Carcinoma | Non Small Cell Lung

United States, France, Canada, Brazil, Poland, Romania, Russian Federation, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Bulgaria, Estonia, India, Malaysia, Singapore, Taiwan, Czech Republic, Argentina, Finland, Hungary, Korea... and more
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR)

Neovascular Age-Related Macular Degeneration

United States, Spain, Korea, Republic of, Czechia, Japan, Singapore, China, Serbia, Lithuania, Taiwan, Australia, Estonia, Austria, Israel, France, Italy, Switzerland, Slovakia, Ukraine, Bulgaria, Portugal, Latvia, Canada, Hungary, Arge... and more
Tennessee Retina
Regeneron Pharmaceuticals

Unknown

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept (TRISTAR)

Neovascular Age-related Macular Degeneration

United States
National Cancer Institute (NCI)

Completed

S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer

United States
Bayer

Completed

A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema (DRAKO)

Macular Edema

United Kingdom
National Cancer Institute (NCI)

Completed

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Recurrent Thyroid Gland Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Follicular Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma

United States
National Cancer Institute (NCI)

Completed

VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Fallopian Tube Cancer | Recurrent Ovarian Epithelial Cancer | Malignant Tumor of Peritoneum

United States
Amin El Sayed Nawar
Tanta University

Completed

Use of Ziv Aflibercept in Different Retinal Diseases

Central Retinal Vein Occlusion With Macular Edema

Egypt
Regeneron Pharmaceuticals
Bayer

Completed

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

Macular Degeneration

United States
National Cancer Institute (NCI)

Completed

Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain Tumor

United States
Bayer

Completed

Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice (MAIA)

Retinal Disease

Mexico
Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Japan, Korea, Republic of, China, Israel, Lithuania, United States, Italy, Spain, Hungary, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Germany, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Latvia, Mal... and more
Kapil Kapoor

Completed

Ziv-aflibercept Efficacy in Better Regulating AMD (ZEBRA)

Wet Macular Degeneration | Wet Age-related Macular Degeneration

United States
Washington University School of Medicine
Regeneron Pharmaceuticals

Completed

Intravitreal Aflibercept Injection for Radiation Retinopathy

Macular Edema | Radiation Retinopathy

United States
Rafic Hariri University Hospital

Unknown

Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection (Zaltrap)

Macular Degeneration | Diabetic Retinopathy | Retinal Vein Occlusion | Choroidal Neovascularization | Retinal Neovascularization | Cystoid Macular Edema | Recurrent Pterygium | Neovascularization

Lebanon
Marashi Eye Clinic

Completed

3 Month Outcome of Ziv-aflibercept for DME

Diabetic Macular Edema
Regeneron Pharmaceuticals
Bayer

Completed

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD) (VIEW1)

Macular Degeneration

United States, Canada
Rafic Hariri University Hospital

Unknown

Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I (ZIV)

Central Retinal Vein Occlusion | Age Related Macular Degeneration

Lebanon
Regeneron Pharmaceuticals

Completed

Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity (BUTTERFLEYE)

Retinopathy of Prematurity

United States, Bulgaria, Hungary, Russian Federation, Thailand, Turkey, Colombia, Czechia, Korea, Republic of, Romania, Slovakia, Taiwan, Vietnam
Regeneron Pharmaceuticals
Bayer

Completed

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration

United States, Canada
Pusan National University Hospital
Bayer

Completed

Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy (VAULT)

Polypoidal Choroidal Vasculopathy | Exudative Age-related Macular Degeneration

Korea, Republic of
Pusan National University Hospital
Novartis

Unknown

Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study) (VIBIM)

Macular Edema, Diabetic

Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Sarcoma | Metastatic Renal Cell Carcinoma | Metastatic Melanoma | Recurrent Renal Cell Carcinoma | Recurrent Melanoma | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Clinical Stage IV Cutaneous Melanoma... and other conditions

United States, Canada
Bayer
Regeneron Pharmaceuticals

Completed

Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema (APOLLON)

Diabetic Retinopathy

France
Bayer

Completed

A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD). (BELUGA)

Neovascular Age-related Macular Degeneration

Belgium
Bayer

Completed

A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America (AQUILA)

Macular Degeneration

Mexico, Argentina, Colombia, Costa Rica
Bayer

Completed

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Macular Degeneration

Spain, Switzerland, Portugal, France, Canada, United Kingdom, Austria, Slovakia, Germany, Hungary, Italy, Lithuania, Czechia, Poland
Bayer

Completed

An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies (GALAXY)

Macular Degeneration

Germany
Bayer
Regeneron Pharmaceuticals

Completed

Study for Collection of Aflibercept Data in Routine Practice (CODEX)

Eye Diseases

France
Bayer
Regeneron Pharmaceuticals

Completed

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO) (JPMS-CRVO)

Retinal Vein Occlusion

Japan

Search clinical trials for: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations